Brett King, MD, PhD

In this MEDcast episode, Raj Chovatiya, MD, PhD, and George Han, MD, PhD, interview Brett King, MD, PhD, to discuss the latest advances in the treatment of alopecia areata.

Expert dermatologists discuss the importance of continued education for physicians treating patients with alopecia areata.

Dr. Brett King shares novel mechanisms of action under research for the treatment of alopecia areata in different age groups.

The expert panel discusses the secondary analysis from the phase 3 BRAVE clinical trials of baricitinib in alopecia areata.

Drs. Raj Chovatiya, George Han, and Brett King discuss the use of baricitinib for the treatment of moderate to severe alopecia areata.

The expert panel highlights the psychosocial burden of alopecia areata on patients and discusses the current treatment paradigm.

Experts in dermatology review how JAK inhibitors will impact dermatology care across the board.

Jerry Bagel, MD, MS, and Brett King, MD, PhD, consider how new advances in oral medication will impact physicians’ and patients’ decision-making when it comes to treatment of alopecia areata, vitiligo, and atopic dermatitis.

Dermatology experts discuss clinical specifics of JAK [Janus kinase] inhibitors and their impact on the treatment of patients with vitiligo and alopecia areata.

Jerry Bagel, MD, MS, and Brett King, MD, PhD, discuss the use of topical JAK inhibitors in alopecia areata, vitiligo, and atopic dermatitis.

Brett King, MD, PhD, shares insight on the dosage efficacy of oral JAK inhibitors abrocitinib and upadacitinib in atopic dermatitis.

Jerry Bagel, MD, MS, and Brett King, MD, PhD, explore how severity of disease factors into treatment selection regarding the use of JAK inhibitors.

Drs Jerry Bagel and Brett King discuss safety considerations and the clinical impact of how boxed warnings for JAK inhibitors highlighting how they affect physician decision-making.

Experts in dermatology review currently available JAK inhibitors for use in patients with dermatological conditions and highlight their differences.

Jerry Bagel, MD, MS, and Brett King, MD, PhD, provide an overview of JAK inhibitors and their mechanisms of action in dermatology care.

Dr. Woolery-Lloyd shares her advice for vitiligo providers and tips for helpful communication with patients.

Drs. Pandya, Rosmarin and King share their enthusiasm about emerging therapies and data that is available for ruxolitinib.

Vitiligo clinical experts discuss the role of maintenance therapy in preventing recurrence of vitiligo.

Drs. Woolery-Lloyd, King and Pandya discuss time to re-pigmentation of different areas in vitiligo.

Drs. Woolery-Lloyd, Rosmarin and Pandya discuss various treatment options for vitiligo and when and where they might use them.

Dr. Rosmarin and other panelists share their thoughts on how to treat different areas of the body and the role of tattoos.

Dr. Pandya shares his conversations with patients about re-pigmentation of segmental and non-segmental vitiligo and treatment options that exist.

Drs. Pandya and King discuss challenges in re-pigmentation, including glabrous skin and areas that may not re-pigment.

Dr. Rosmarin provides an overview of models of re-pigmentation in vitiligo.

Drs. Rosmarin and King discuss the importance of shared-decision making and understanding of patient goals in managing vitiligo.

Drs. Pandya and King discuss patient’s visit and how providers can help set expectations about the disease course.

Dr. Woolery-Lloyd shares her approach to talking to patients about vitiligo.

Drs Woolery-Lloyd, King and Pandya share how vitiligo affects patients’ quality of life.

Drs Rosmarin, King, and Pandya give an overview of clinical presentation and classification of vitiligo.

Drs Pandya discusses vitiligo pathophysiology, the role of genetic and environmental factors, and how to communicate with patients about it.